A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate.
Mattsson
J
J
Department of Transplantation Surgery, Clinical Immunology, Medicine and Pediatrics, Karolinska Institute, Huddinge Hospital, Sweden.
Ringdén
O
O
Aschan
J
J
Barkholt
L
L
Dalianis
T
T
Hägglund
H
H
Ljungman
P
P
Lönnqvist
B
B
Tollemar
J
J
Winiarski
J
J
Remberger
M
M
D000208:Acute Disease; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003141:Communicable Diseases / Q000401:mortality*; D016572:Cyclosporine / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control*; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007938:Leukemia / Q000628:therapy; D019520:Living Donors; D008223:Lymphoma / Q000628:therapy; D008661:Metabolism, Inborn Errors / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009679:Nuclear Family
D000961:Antilymphocyte Serum; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate